Kiora Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for retinal diseases that threaten vision. Based in Encinitas, California, the company targets biological pathways involved in these conditions with innovative small molecules. Its goal is to develop treatments that may slow, stop, or restore vision loss, particularly for diseases with limited or no effective treatment options.

Kiora’s research and development pipeline includes KIO-301 and KIO-104. The company provides information about its pipeline, scientific work, clinical trials, and related publications through its Pipeline & Science resources. Its website also shares company news and media, and offers information for investors, including access to corporate leadership details such as its executive team, board of directors, and scientific advisory board.

Kiora’s work centers on advancing potential therapies for retinal disease rather than offering established products or clinical services. The company invites visitors to learn about its research programs and follow developments as it works toward addressing unmet needs in vision care.